InnovAge Holding (INNV) has posted a mixed Q3 2026 result, with revenue at US$251.9 million and a basic EPS loss of US$0.22 alongside net income of US$29.5 million in the red. The company’s revenue increased from US$218.1 million in Q3 2025 to US$251.9 million in Q3 2026, while quarterly EPS moved from a loss of US$0.08 to a loss of US$0.22 over the same period. This sets up a narrative that now focuses on how quickly margins can be repaired to align with the growth in the top line.

See our full analysis for InnovAge Holding.

With the headline numbers on the table, the next step is to compare these results with the widely followed narratives around growth, profitability and risk to see which views hold up and which might need to be reconsidered.

Revenue Near US$950m On Trailing Basis

• On a trailing 12 month view to Q3 2026, InnovAge generated US$949.2 million in total revenue, up from US$806.6 million on the same trailing basis at Q2 2025.
• Consensus narrative emphasises enrollment growth and geographic expansion as key revenue drivers, and the revenue step up on the trailing view sits alongside that story, while:
  • Revenue on the trailing basis moved from US$853.7 million at Q4 2025 to US$949.2 million at Q3 2026, which lines up with the focus on expanding into new markets and underpenetrated states.
  • At the same time, revenue growth is forecast at 6.8% per year versus a 11.3% market forecast, which shows that even with expansion, projected top line growth is slower than the broader US market that the bullish view references.

Bulls point to enrollment growth and geographic expansion as long term revenue engines, and this trailing revenue profile is a good place to stress test that thesis further, including how much growth investors are actually paying for right now 🐂 InnovAge Holding Bull Case

Swings From Q2 Profit To Q3 US$29.5m Loss

• Net income moved from US$10.6 million in Q2 2026 to a loss of US$29.5 million in Q3 2026, with basic EPS shifting from a profit of US$0.08 to a loss of US$0.22 over just one quarter.
• Bears highlight accelerating costs, regulatory exposure and de novo losses as threats to profitability, and the quarter to quarter move into a larger loss connects directly to those concerns, because:
  • On a trailing 12 month basis, net income was a loss of US$11.6 million at Q3 2026 compared with a loss of US$30.3 million a year earlier, so the business is still loss making even after periods of positive quarterly EPS earlier in 2026.
  • Management commentary in the bearish narrative flags cost of care up 17.6% year over year against 13% revenue growth and Q3 de novo center losses of US$3.5 million, which is consistent with the data showing profits reverting back to a sizeable quarterly loss.

Skeptics focus on whether rising costs and new center losses can be contained fast enough, and these profit swings give a concrete backdrop for testing how fragile the path to profitability might be 🐻 InnovAge Holding Bear Case

DCF Fair Value US$26.72 Versus US$8.12 Price

• The DCF fair value in the data is US$26.72 per share compared with a current share price of US$8.12 and an analyst price target of US$7.00, while the stock trades on a P/S of 1.2x in line with the US Healthcare industry average and slightly above the 1.1x peer level.
• What stands out in the bullish case is the tension between that higher DCF fair value and current losses, because:
  • Earnings are forecast to grow 85.02% per year with a move to profitability within three years from an unprofitable trailing 12 month base of a US$11.6 million loss, which is a steep improvement embedded in the valuation model.
  • At the same time, the analyst price target of US$7.00 sits below the current US$8.12 price, which suggests that while the DCF model points to US$26.72, at least some analysts using US$1.2 billion revenue and US$94.2 million earnings by about April 2029 are more conservative on where the stock might trade.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for InnovAge Holding on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Sentiment across the narratives is split, so now is a good moment to look through the numbers yourself and test how convincing each side feels. To see what optimistic investors are focusing on, review the 2 key rewards

Explore Alternatives

InnovAge is still reporting losses and facing cost pressures that challenge the bullish expectations embedded in its DCF fair value and growth narratives.

If this mix of ongoing losses and earnings uncertainty feels uncomfortable, you can quickly focus on companies with steadier profiles by checking out the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.